.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Yupelri for Chronic Obstructive Pulmonary Disease

February 13, 2019

Drew Boxler

Yupelri (revefenacin, Mylan®)

Indications: Patients with chronic obstructive pulmonary disease

Dosage: One 175 mcg vial (3 mL) once daily.

Contraindications: hypersensitivity to revefenacin or any component of this product.

Click here for more prescribing information